Latest From Illumina Inc.
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
Roche and Illumina have entered a 15-year, non-exclusive partnership to expand access to next-generation sequencing- based testing in cancer care.
Illumina had planned to acquire Pacific Biosciences to add the company's “long-read” gene sequencing systems to Illumina's own range of "short-read" technologies. However, the UK’s Competition and Markets Authority and the US Federal Trade Commission concluded that the deal would significantly reduce competition in the DNA sequencing market.
Drug Discovery Tools
- Nanotechnology, Chips, etc.
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Illumina Inc.
- Senior Management
Francis deSouza, Pres. & CEO
Sam Samad, CFO
Mark Van Oene, SVP, Chief Commercial Officer
Garrett Hampton, PhD, EVP, Clinical Genomics
Omead Ostadan, EVP, Products & Ops
Joydeep Goswami, SVP, Corp Dev. & Strategic Planning
Mostafa Ronaghi, PhD, SVP, CTO
- Contact Info
Phone: (858) 202-4500
5200 Illumina Way
San Diego, CA 92122
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.